Immunotherapy of human cancers using gene modified T lymphocytes.
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.
Center for Cell and Gene Therapy, Department of Medicine, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, 6621 Fannin Avenue, Houston, TX 77030, USA.
Juan F
JF
Vera
Malcolm K
MK
Brenner
Gianpietro
G
Dotti
D000941:Antigens / Q000276:immunology; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D000941:Antigens